What it's for (Indications)
- Insulin aspart and insulin degludec (Ryzodeg) is specifically indicated for the improvement of glycemic control in adult patients diagnosed with diabetes mellitus.
- This dual-acting insulin analogue formulation is designed to provide comprehensive glucose management by addressing both basal and prandial insulin requirements within a single injection.
- It is approved for use in individuals with Type 1 diabetes, where pancreatic beta-cell destruction leads to absolute insulin deficiency, necessitating exogenous insulin replacement to maintain life.
- Additionally, it is indicated for adults with Type 2 diabetes who require insulin therapy to achieve their individualized glycemic targets, particularly when oral antidiabetic agents or other injectable therapies are insufficient, or when a combined basal and mealtime insulin approach is clinically warranted to optimize fasting, pre-meal, and post-prandial blood glucose levels.
- The fixed-ratio combination simplifies treatment regimens while effectively targeting hyperglycemia throughout the day and post-meal periods, contributing to better long-term outcomes in diabetes management by reducing HbA1c and minimizing glycemic variability.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage must be individualized based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goals. Administration and titration should be determined by a healthcare professional. |
Safety & Warnings
Common Side Effects
- Common side effects include injection site reactions, weight gain, and hypokalemia (low potassium level in the blood, potentially causing muscle weakness).
- Hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) can also occur.
- Allergic reactions are rare.
- Consult a healthcare professional for a comprehensive list of potential side effects.
Serious Warnings
- Black Box Warning: Serious Warnings: While insulin aspart and insulin degludec (Ryzodeg) does not carry a formal FDA Black Box Warning, healthcare professionals and patients must be acutely aware of several significant safety concerns. The most critical risk associated with insulin therapy, including Ryzodeg, is hypoglycemia, which can range from mild to severe, potentially leading to unconsciousness, seizures, brain damage, and even death if not promptly recognized and treated. Patients should be educated on the symptoms of hypoglycemia, such as sweating, tremors, dizziness, confusion, and palpitations, and how to manage it effectively by consuming fast-acting carbohydrates. Furthermore, severe hypersensitivity reactions, including life-threatening anaphylaxis, are rare but possible with any insulin product. Patients should be advised to seek immediate medical attention if they experience symptoms of a severe allergic reaction, such as widespread rash, intense itching, hives, shortness of breath, wheezing, or swelling of the face, lips, tongue, or throat. Careful and consistent monitoring of blood glucose levels is paramount to mitigate these risks and ensure safe and effective glycemic management, alongside regular assessment for signs of adverse reactions and appropriate dose adjustments by a healthcare provider.
- Pregnancy: No known risk in pregnant females, but consultation with a healthcare provider is advised for further details.
- Lactation: No known risk in lactating females, but consultation with a healthcare provider is advised for further details.
- Driving: This medication may affect your ability to drive; avoid driving until effects are known.
- Alcohol: Avoid consuming alcohol while taking this medicine.
- Patients should inform their healthcare providers of their complete medical history before starting this medication.
- Caution is advised for patients with a history of hypoglycemia.
How it Works (Mechanism of Action)
Insulin aspart and insulin degludec is a co-formulation consisting of two distinct insulin analogues, each with a unique pharmacological profile, working synergistically to regulate glucose metabolism. Insulin degludec acts as an ultra-long-acting basal insulin. Following subcutaneous injection, it forms soluble multi-hexamers that slowly and continuously release insulin monomers into the circulation, providing a flat and prolonged glucose-lowering effect lasting up to 42 hours, thereby covering basal insulin requirements. Its primary actions involve enhancing peripheral glucose uptake by insulin-sensitive tissues such as skeletal muscle and adipose tissue, while simultaneously suppressing endogenous hepatic glucose production (gluconeogenesis and glycogenolysis). Insulin aspart is a rapid-acting insulin analogue. Due to its modified amino acid sequence (proline at B28 replaced by aspartic acid), it dissociates quickly into monomers after subcutaneous injection, leading to rapid absorption and a swift onset of action (typically within 10-20 minutes). This allows it to effectively control post-prandial glucose excursions by rapidly increasing glucose uptake into cells and inhibiting hepatic glucose output after meals. Both insulin analogues exert their effects by binding to the specific insulin receptors located on the surface of target cells (e.g., liver, muscle, adipose tissue), thereby activating a cascade of intracellular signaling pathways that promote glucose utilization, protein synthesis, and lipid storage, while inhibiting glucose-producing processes.
Commercial Brands (Alternatives)
No other brands found for this formula.